home / stock / bivi / bivi news

BIVI News and Press, BioVie Inc. From 08/09/21

Stock Information
Company Name: BioVie Inc.
Stock Symbol: BIVI
Market: NASDAQ
Website: biovieinc.com
Menu
BIVI BIVI Quote BIVI Short BIVI News BIVI Articles BIVI Message Board
Get BIVI Alerts

News, Short Squeeze, Breakout and More Instantly...
BIVI - WPG, NCTY, ANY among mid-day movers

Gainers: Golden Nugget Online Gaming (NASDAQ:GNOG) +48%. Tarena International (NASDAQ:TEDU) +43%. SCWorx (NASDAQ:WORX) +32%. Select Interior Concepts (NASDAQ:SIC) +30%. Washington Prime Group (NYSE:WPG) +30%. The9 Limited (NASDAQ:NCTY) +27%. Sphere 3D (NASDAQ:ANY) +26%. Liminal BioSciences (N...
BIVI - SCWorx, Liminal BioSciences leads healthcare gainers; Axsome Therapeutics, BioVie among major losers

Gainers: SCWorx (NASDAQ:WORX) +32%, Liminal BioSciences (NASDAQ:LMNL) +28%, Allied Healthcare Products (NASDAQ:AHPI) +20%, Windtree Therapeutics (NASDAQ:WINT) +17%, NRx Pharmaceuticals (NASDAQ:NRXP) +15%. Losers: Axsome Therapeutics (NASDAQ:AXSM) -42%,&...

BIVI - BioVie Inc. Announces Pricing of Public Offering of Common Stock

SANTA MONICA, Calif., Aug. 08, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders, liver disease and cert...

BIVI - BioVie Inc. Announces Proposed Public Offering of Common Stock

SANTA MONICA, Calif., Aug. 06, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders, liver disease and cert...
BIVI - BioVie starts enrollment in late-stage NE3107 Alzheimer's Disease trial

BioVie (NASDAQ:BIVI) has enrolled the first patient into the NM101 Phase III clinical study testing NE3107 for the treatment of Alzheimer’s Disease (AD). The NM101 study is a potentially pivotal Phase 3, randomized, double blind, placebo-controlled, US multicenter study of NE3107 in 31...

BIVI - BioVie Announces First Patient Enrolled in Phase 3 Study of NE3107 in Alzheimer's Disease

SANTA MONICA, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug candidates for the treatment of neurological and neurodegenerative disorders, liver disease and certain cancers, today announced th...

BIVI - BioVie Presents Data Supporting use of NE3107 in the Treatment of Alzheimer's Disease at 2021 Alzheimer's Association International Conference

SANTA MONICA, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of liver disease, neurodegenerative disease and certain cancers, announced today that a poster by Christopher L Reading, PhD, BioVie’s ...
BIVI - BioVie to Present Rationale for use of NE3107 for the Treatment of Alzheimer's Disease at 2021 Alzheimer's Association International Conference

SANTA MONICA, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of liver disease, neurodegenerative disease and certain cancers, announced today that Poster 55458 entitled “ Rationale for an Anti-i...

BIVI - BioVie highlights Alzheimer's disease treatment's potential ahead of upcoming late-stage trial

BioVie (BIVI) highlights article summarizing the scientific rationale for the company’s upcoming late-stage trial of NE3107 in Alzheimer’s disease published in Neurodegenerative Disease Management.The article details rationale for an anti-inflammatory insulin sensitizer in Alzhe...

BIVI - Basis for BioVie's Phase 3 Clinical Trial of NE3107 in the Treatment of Alzheimer's Disease Published in Neurodegenerative Disease Management

SANTA MONICA, Calif., July 16, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of liver disease, neurodegenerative disease and certain cancers, announced today that an article summarizing the scientific rationale for the ...
Previous 10 Next 10